Posted by Michael Wonder on 06 Jan 2023
Infex's novel AMR drug candidate MET-X receives FDA QIDP designation
5 January 2023 - Infex Therapeutics is pleased to announce that the US FDA has granted qualified infectious disease product designation to MET-X, the Company’s broad spectrum metallo beta lactamase inhibitor.
MET-X is a resistance bypass treatment which targets gram negative Enterobacterales.
